People · Operator
Named in public records as an officer, director or promoter · active 2010–2025 · Biotechnology, Pharmaceuticals, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Adaptive Biotechnologies Corp | — | Biotechnology | Series D+ | $614.0M | $8.0B | 2012 |
| PMV Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $73.7M | $2.6B | 2017 |
| GeneCentric Therapeutics, Inc. | — | Biotechnology | Series A | $21.6M | $6.7M | 2020 |
| Selventa, Inc. | — | Other Health Care | Series A | $5.5M | $100.2M | 2010 |
Arnold Levine at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Arnold Levine on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Thompson | 1 | 16 |
| Clay Thorp | 1 | 10 |
| Michael Grey | 1 | 10 |
| Arnold Oronsky | 1 | 10 |
| Noubar Afeyan | 1 | 9 |
| Mitchell Bloom | 1 | 6 |
| Lee Huntsman | 1 | 5 |
| Chad Robins | 1 | 5 |
| Peter Neupert | 1 | 4 |
| Sean McCarthy | 1 | 3 |
| Chris Thomajan | 1 | 3 |
| John Stuelpnagel | 1 | 3 |
| Michael Milburn | 1 | 3 |
| David De Graaf | 1 | 3 |
| Harlan Robins | 1 | 2 |
| Michael Pavia | 1 | 2 |
| DAVID MACK | 1 | 2 |
| Craig Weissman | 1 | 2 |
| Jim Matheson | 1 | 2 |
| Chris Carlson | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.